Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Molecular BioLife International, Inc.
WARNING LETTER
•Molecular BioLife International, Inc.•April 15, 2021

Molecular BioLife International, Inc. – FDA Warning Letter, Apr 15, 2021

Record Details

The FDA issued a Warning Letter to Molecular Biolife on April 15, 2021, following a review of their website, www.molecularbiolife.com, from March to April 2021. The FDA determined that the company was taking orders for "Shark 2 Collagen" and "Balanced Kollagen," which are marketed with claims establishing them as unapproved new drugs and misbranded drugs under the Federal Food, Drug, and Cosmetic Act (the Act).

The products are deemed drugs under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] due to claims on the website and associated white papers indicating their intended use in the cure, mitigation, treatment, or prevention of diseases. Examples of such claims for Shark 2 Collagen include treating cancer, osteoarthritis, rheumatoid arthritis, psoriasis, lupus, eczema, and various pain and inflammatory conditions. For Balanced Kollagen, claims include preventing chronic illnesses, relieving pain, preventing joint disorders, rebuilding organs, reducing anxiety, and treating conditions like osteoarthritis, CJD symptoms, rheumatoid arthritis, lupus, gout, fibromyalgia, osteoporosis, and obesity.

Since these products are not generally recognized as safe and effective for their claimed uses, they are considered "new drugs" under section 201(p) of the Act [21 U.S.C. 321(p)]

Company
Molecular BioLife International, Inc.
Inspection date
April 15, 2021
Product type
Food
Office
Office of Human and Animal Food West Division II
Person
  • Jeffrey Moody (Director of Investigations Branch)
View Company Profile

ID · 01650e67-b5d2-4310-b284-8250c490539d

Violation Codes8
21 U.S.C. 321(g)(1)(B)21 U.S.C. 321(p)21 U.S.C. 331(d)21.U.S.C. 355(a)21 U.S.C. 352(f)(1)21 CFR 201.521 U.S.C. 353(b)(1)(A)21 U.S.C. 331(a)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Molecular BioLife International, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.